Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Efficacy of ICI 182,780 (Faslodex) in the Treatment of Systemic Lupus Erythematosus: Clinical, Serologic, Molecular

NCT00417430 is registered in ClinicalTrials.gov with The Center for Rheumatic Disease, Allergy, & Immunology as lead sponsor.

NCT NCT00417430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00417430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Efficacy of ICI 182,780 (Faslodex) in the Treatment of Systemic Lupus Erythematosus: Clinical, Serologic, Molecular
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
December 31, 2006
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus